PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
1.47%
ROE exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.56%. Joel Greenblatt would check if high returns reflect a sustainable advantage.
1.30%
ROA of 1.30% while Drug Manufacturers - Specialty & Generic median is zero. Peter Lynch would see if minimal profitability can widen over time.
-0.66%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate whether a turnaround is viable.
95.39%
Gross margin exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 61.43%. Joel Greenblatt would see if cost leadership or brand drives the difference.
-77.87%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for a path to operational turnaround.
159.31%
Net margin of 159.31% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss would examine if modest profitability can expand.